Epredia lanza impresoras láser de casete diseñadas para mejorar el seguimiento de muestras y la eficiencia del laboratorio

Portsmouth, NH
November 1, 2024

Epredia, a global leader in precision cancer diagnostics and subsidiary of PHC Holdings Corporation (TSE 6523), announces its SlideMateTM Laser slide printer has received an Innovative Technology designation for improving laboratory efficiency and sample traceability from Vizient, Inc., the largest healthcare provider performance improvement company in the country. Epredia exhibited SlideMate Laser at the Vizient Innovative Technology Exchange Sept. 18 in Las Vegas.

Each year, healthcare experts serving on Vizient provider-led councils review select products and technologies for their potential to enhance clinical care, patient safety, or healthcare worker safety or to improve business operations of healthcare organizations. Innovative Technology designations are awarded to previously contracted products to signal to healthcare providers the impact of these innovations on patient care and the business models of healthcare organizations.
Epredia’s SlideMate portfolio of slide printers is used in the cancer diagnostics process to identify and help track tissue samples. The company designed SlideMate Laser for clinical laboratories of any size looking to improve sample traceability. SlideMate Laser provides high-resolution, 600-dpi laser printing on microscope slides, enabling laboratories to include more identifying information directly on the tab of the slides that pathologists use in the cancer diagnostics workflow. This technology can embed up to 50 characters in a barcode on each slide, compared to 23 characters with traditional thermal transfer and ink jet technologies, improving both patient sample tracking and efficiency. 

SlideMate Laser also enhances laboratory efficiency by optimizing the slide movements through the printer and reducing potential downtime compared to thermal transfer and ink jet printers. Without the need to purchase, ink, bulbs or tape for slide printers, users can expect lower operational costs. With both on-demand and batch printing options, SlideMate Laser can integrate into a range of workflows. The laser printer’s software is easy to use and can be directly interfaced to a Laboratory Information System.

SlideMate Laser is the latest addition to Epredia’s world-class portfolio of precision cancer diagnostics products and services that provide a seamless end-to-end laboratory workflow. Epredia also offers the specialized slides designed for use with SlideMate Laser to help laboratories make a smooth transition to precision laser printing.

Steven Lynum, President of Epredia, said, “We set out to transform the anatomical pathology market with precision cancer diagnostics solutions. The Vizient Innovative Technology Designation is a true honor, and further proof that SlideMate Laser contributes to our goal of providing a seamless end-to-end laboratory workflow. Our team remains focused on improving patient outcomes by enabling pathologists to do their best work.”

“Congratulations to Epredia for achieving this peer-designated status,” said Kelly Flaharty, senior director contract services and Vizient Innovative Technology Program leader. “Our customer council deemed the SlideMate Laser worthy of this designation for its potential to make a real difference in the healthcare industry.”

Vizient represents a diverse customer base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute healthcare providers and has a portfolio that represents more than $140 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with member-led councils and task forces to evaluate products for their potential to bring real innovation to healthcare. Vizient may award a contract to products deemed worthy of the Innovative Technology designation outside of the competitive bid cycle. 

Acerca de Epredia

Epredia es líder mundial en el campo de la patología anatómica, proporcionando soluciones integrales para el diagnóstico de precisión del cáncer y el diagnóstico de tejidos. Impulsada por marcas clave como Erie Scientific, Menzel-Gläser, Microm, Shandon y Richard-Allan Scientific, la cartera de productos de Epredia incluye portaobjetos de microscopio, instrumentos y consumibles. Epredia se creó tras la adquisición del negocio de Anatomía Patológica de Thermo Fisher Scientific por parte de PHC Holdings en 2019. Epredia tiene operaciones en los principales centros de Estados Unidos, Reino Unido, Alemania, Suiza y China, con un total de alrededor de 1200 empleados. Epredia se compromete a cumplir su misión de mejorar vidas mejorando el diagnóstico del cáncer para pacientes de todo el mundo. Para más información sobre Epredia y sus productos, visite www.epredia.com

Acerca de PHC Holdings Corporation (Grupo PHC)

PHC Holdings Corporation (TSE 6523) es una compañía global de salud con la misión de contribuir a la salud de la sociedad a través de soluciones sanitarias que tengan un impacto positivo y mejoren la vida de las personas. Sus filiales (denominadas colectivamente Grupo PHC) incluyen PHC Corporation, Epredia, Ascensia Diabetes Care, LSI Medience Corporation, Mediford y Wemex. Juntas, estas empresas desarrollan, fabrican, venden y ofrecen soluciones para el control de la diabetes, soluciones sanitarias, ciencias de la vida y diagnóstico. Las ventas netas consolidadas del Grupo PHC en el año fiscal 2022 ascendieron a 356.400 millones de yenes japoneses, con una distribución mundial de productos y servicios en más de 125 países.
www.phchd.com

Para más información, póngase en contacto con:

Julia Cottrill
Comunicación corporativa del Grupo HPC
Correo electrónico: julia.cottrill@phchd.com